Shots:
- US FDA has granted Orphan Drug Designation (ODD) to SN BioScience’s SNB-101 for the treatment of gastric cancer, including gastroesophageal junction cancer
- SNB-101 is currently under P-Ib/II development for small cell lung cancer and is being evaluated across multiple solid tumor indications in Korea, Europe and US
- SNB-101 is a polymer nanoparticle formulation of SN-38 which previously received US FDA ODDs for small cell lung cancer (Jul’23) and pancreatic cancer (Feb’24), supporting SN BioScience’s to expand clinical development and indications
Ref: PR Newswire | Image: SN BioScience | Press Release
Related News: Amgen Reports Data from the P-III (FORTITUDE-101) Study Evaluating Bemarituzumab in FGFR2b+ 1L Gastric Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
